Filing Flows › Comparisons › PALI vs ATTO
Palisade Bio vs Attovia Therapeutics: PALI and ATTO compared
Palisade Bio is the larger company: $500K of revenue in its latest quarter (Q2 2026) against $450K for Attovia Therapeutics (Q2 2026).
Where the money goes: PALI and ATTO
Palisade Bio (PALI) · Q2 2026
Palisade Bio, Q2 2026: revenue $500K, net loss $10.6M, operating cash flow −$7.6M. The chart follows the revenue to costs, profit and cash.
Attovia Therapeutics (ATTO) · Q2 2026
Attovia Therapeutics, Q2 2026: revenue $450K, net loss $20.7M. The chart follows the revenue to costs, profit and cash.
| Palisade Bio (PALI) | Attovia Therapeutics (ATTO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $500K | $450K |
| Operating margin | n/m | n/m |
| Net earnings | −$10.6M | −$20.7M |
| Operating cash flow | −$7.6M | — |
Questions
Which is bigger, Palisade Bio or Attovia Therapeutics?
Palisade Bio is the larger company: $500K of revenue in its latest quarter (Q2 2026) against $450K for Attovia Therapeutics (Q2 2026).
More: Palisade Bio earnings · how Palisade Bio makes money · Attovia Therapeutics earnings · how Attovia Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Sep 2, 2026). Fiscal quarters can end on different dates. Not investment advice.